Last reviewed · How we verify
ella
At a glance
| Generic name | ella |
|---|---|
| Sponsor | HRA Pharma |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Mammogram Pretreatment With Ulipristal Acetate (PHASE2)
- Multicenter Prospective Non-randomized Controlled Study of Ella Photodynamic Therapy for Cervical HSIL/CIN2 (NA)
- Multicenter Prospective Non-randomized Controlled Study of ALA-PDT for LSIL With HPV16/18 Infection (NA)
- Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg (PHASE4)
- Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive (PHASE2)
- Non-interventional Study to Evaluate Long Term Safety, Prescription Management Patterns of Esmya in a Long Term Setting
- Comfortage - AD Prevention Strategies (NA)
- PROACT Pilot Trial
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ella CI brief — competitive landscape report
- ella updates RSS · CI watch RSS
- HRA Pharma portfolio CI